英国神经病学家协会 (ABN) 自体免疫性骨髓灰质炎管理指南 (2025年更新)
Saiju Jacob1,2, Maria Elena Farrugia3, Channa Hewamadduma4,5
1Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, UK s.jacob@bham.ac.uk.
Practical neurology
|September 12, 2025
概括
英国神经病学家协会2025年关于肌痛性骨髓灰质炎 (MG) 管理的指导方针建议每天服用类固醇和早期切除甲状腺. 新证据支持早期rituximab和针对性治疗耐火性MG.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 临床医学 临床医学
背景情况:
- 自免疫性骨髓灰质炎 (MG) 管理已经显著发展.
- 2015年以前的指导方针需要根据最近的研究进行更新.
- 标准治疗方案需要改进,以纳入新的证据.
研究的目的:
- 概述2025年英国神经科医生协会 (ABN) 关于管理肌痛性骨髓灰质炎 (MG) 的指导方针中的关键更新.
- 要突出与2015年ABN指南相比的重大变化.
- 将最近的研究成果纳入MG临床实践建议中.
主要方法:
- 审查最近的研究和出版物与肌痛性骨髓灰质炎管理相关.
- 对既有和新型疗法进行随机对照试验 (RCT) 的分析.
- 将2025年指南建议与2015年指南进行比较.
主要成果:
- 现在建议每天使用类固醇方案,而不是替代日方案.
- 重点是早期乳腺切除术对MG患者的好处.
- 随机对照试验证据支持早期使用rituximab (一般发病1年内).
- 新出现的证据支持新的向疗法,包括补充剂和FcRn抑制剂,用于耐火性MG.
结论:
- 2025年ABN指南反映了肌痛性骨髓灰质炎治疗的重大进展.
- 更新的建议包括改变类固醇的使用,强调早期的甲状腺切除术,并整合rituximab和新疗法.
- 这些更新旨在改善患有严重骨髓灰质炎的患者的治疗结果,特别是那些对常规治疗无反应的患者.
更多相关视频
05:44A Rapid, Simple, and Standardized Homogenization Method to Prepare Antigen/Adjuvant Emulsions for Inducing Experimental Autoimmune Encephalomyelitis
Published on: December 9, 2022
3.8K
05:55Author Spotlight: Novel Assay for Studying B-Cell Responses in Multiple Sclerosis Research
Published on: December 1, 2023
1.4K
相关概念视频
01:26Chemical Synapses
9.5K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
9.5K
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
1.8K
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
1.8K
01:20Myasthenia Gravis: Overview and Treatment
3.7K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
3.7K
01:15Myasthenia Gravis: Diagnostic Tests
3.3K
Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
3.3K
01:26Chemical Synapses
10.9K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
10.9K
01:22Myasthenia Gravis ll: Pathophysiology
53
The disease process of myasthenia gravis begins at the neuromuscular junction, where antibodies attack key proteins needed for muscle activation. This immune reaction weakens signal transmission, leading to the characteristic muscle fatigue and weakness that define the condition.Immune-Mediated DamageIn most individuals, antibodies target acetylcholine receptors (AChRs) on the postsynaptic membrane of muscle cells. By blocking acetylcholine binding, these antibodies prevent the nerve signal...
53